1067915-34-7

Basic information

• Product Name: ethyl 1-benzyl-5,5-difluoro-4-oxopiperidine-3-carboxylate
• Synonyms: ethyl 1-benzyl-5,5-difluoro-4-oxopiperidine-3-carboxylate;Ethyl 1-benzyl-5,5-difluo...;Ethyl 1-benzyl-5,5-difluoro-4-oxo-piperidin-3-carboxylate;5,5-Difluoro-4-oxo-1-(phenylmethyl)-3-piperidinecarboxylic acid ethyl ester
• CAS NO: 1067915-34-7
• Molecular Formula: C₁₅H₁₇F₂NO₃
• Molecular Weight: 297.2971864
• Mol File: 1067915-34-7.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 365.6±42.0 °C(Predicted)
• Appearance: /
• Density: 1.25±0.1 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: 6.93±0.40(Predicted)
• CAS DataBase Reference: ethyl 1-benzyl-5,5-difluoro-4-oxopiperidine-3-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: ethyl 1-benzyl-5,5-difluoro-4-oxopiperidine-3-carboxylate(1067915-34-7)
• EPA Substance Registry System: ethyl 1-benzyl-5,5-difluoro-4-oxopiperidine-3-carboxylate(1067915-34-7)

Safety Data

• Hazardous Substances Data: 1067915-34-7(Hazardous Substances Data)

Usage

General Description

Ethyl 1-benzyl-5,5-difluoro-4-oxopiperidine-3-carboxylate is a chemical compound with the molecular formula C17H19F2NO4. It is a synthetic molecule not naturally found in the environment. Its structure comprises an ethyl carboxylate group forming an ester with a piperidine ring, which includes two fluorine atoms and a benzyl group attached to it. Very little information exists concerning its properties, applications, or potential hazards, likely because it is used predominantly within highly specialized fields such as pharmaceutical or chemical research and development sectors. As such, its handling and use would typically be restricted to trained professionals. It’s not registered under REACH (Registration, Evaluation, Authorisation and restriction of Chemicals), which implies it's not widely produced or used in the European Union.

Upstream product

• 23583-21-3 ethyl-3-benzylamino propionate 
• 851314-54-0 ethyl N-(1H-1,2,3-benzotriazol-1-ylmethyl)-N-(phenylmethyl)-beta-alaninate 
• 851314-55-1 ethyl N-[3-(ethyloxy)-2,2-difluoro-3-oxopropyl]-N-(phenylmethyl)-beta-alaninate 

Downstream Products

• 1067914-83-3 tert-butyl 3,3-difluoro-4,4-dihydroxypiperidine-1-carboxylate 
• 1067914-82-2 (±)-tert-butyl 4-(benzylamino)-3,3-difluoropiperidine-1-carboxylate 
• 1820679-70-6 (±)-tert-butyl 4-amino-3,3-difluoropiperidine-1-carboxylate 
• 851314-31-3 C₃₆H₃₅Cl₃F₄N₂O₄ 
• 851314-26-6 4-{4-[3-(2-chloro-3,6-difluorophenoxy)propyl]phenyl}-5,5-difluoro-1,2,5,6-tetrahydropyridine-3-carboxylic acid cyclopropyl-(2,3-dichlorobenzyl)amide 
• 851314-50-6 4-{4-[3-(2-chloro-3,6-difluorophenoxy)propyl]phenyl}-5,5-difluoro-5,6-dihydro-2H-pyridine-1,3-dicarboxylic acid 1-tert-butyl ester 3-ethyl ester 
• 851314-53-9 4-{4-[3-(2-chloro-3,6-difluorophenoxy)propyl]phenyl}-5,5-difluoro-5,6-dihydro-2H-pyridine-1,3-dicarboxylic acid 1-tert-butyl ester 
• 851314-47-1 5,5-difluoro-4-[4-(3-hydroxypropyl)phenyl]-5,6-dihydro-2H-pyridine-1,3-dicarboxylic acid 1-tert-butyl ester 3-ethyl ester 
• 1820679-70-6 (+)-(R*)-tert-butyl 4-amino-3,3-difluoropiperidine-1-carboxylate 
• 1239596-54-3 3,3-difluoropiperidin-4-ol 
• 851314-41-5 1-benzyl-5,5-difluoro-4-trifluoromethanesulfonyloxy-1,2,5,6-tetrahydro-pyridine-3-carboxylic acid ethyl ester 

Relevant articles and documents

3,3-DIFLUORO-PIPERIDINE DERIVATIVES AS NR2B NMDA RECEPTOR ANTAGONISTS

Disclosed are chemical entities of Formula (I): wherein X, Y, Z, R1, R3, R4 and R5 are defined herein, as NR2B subtype selective receptor antagonists. Also disclosed are pharmaceutical compositions comprising a chemical entity of Formula (I), and methods of treating various diseases and disorders associated with NR2B antagonism, e.g., diseases and disorders of the CNS, such as depression, by administering a chemical entity of Formula (I).

TETRAHYDROPYRIDINE DERIVATIVES

The invention relates to novel tetrahydropyridine derivatives and use thereof as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more of those compounds and especially their use as inhibitors of renin. (I) wherein X and Y represent independently hydrogen, fluorine or a methyl group; X and Y do not represent both hydrogen at the same time or X and Y may together form a cyclopropyl ring; W represents a phenyl or a heteroaryl, the heteroaryl ring being a six-membered and non-fused ring, the phenyl ring and the heteroaryl are substituted with V in position 3 or 4; A and B independently represent-O-;-S-;-SO-or-SO2-; U represents aryl or heteroaryl; T represents-CONR1-;-(CH2)pOCO-;-(CH2)pN(R1)CO-;-(CH2)p N(R1)SO2-;-COO-;-(CH2)pOCONR1-or-(CH2)pN(R2)CONR1-; R1 and R2 independently respresent hydrogen; lower alkyl; lower alkenyl; lower alkynil; cycloalkyl; aryl-lower alkyl, heteroaryl-lower alkyl or cycloalkyl-lower alkyl; Q represents lower alkylene or lower alkenylene; M represents hydrogen; cycloalkyl; aryl; heterocyclyl or heteroaryl: